The beneficial effect of tamoxifen therapy in patients with resected adenocarcinoma of the pancreas

Hepato-Gastroenterology

Volumn 43, Issue 11, 1996, Pages 1225-1229

  Horimi, Tadashi ^a   Takasaki, Motohiro ^a   Toki, Akira ^a   Nishimura, Wataru ^a   Morita, Sogiro ^a  

^a National Hospital Organization   (Japan)

Author keywords

Adenocarcinoma of the pancreas; Estrogen receptor; Surgical reduction of the volume of the carcinoma; Tamoxifen therapy

Indexed keywords

KRESTIN; MITOMYCIN; PICIBANIL; TAMOXIFEN; TEGAFUR;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER HORMONE THERAPY; CANCER SURGERY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; SURGICAL TECHNIQUE; SURVIVAL RATE;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PANCREATIC NEOPLASMS; RETROSPECTIVE STUDIES; TAMOXIFEN;

EID: 0029860594     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Andren-Sandberg A, Rosenthal HE: Estrogen receptors in the pancreas. J Steroid Biochem 1974;5:969-975
2. Stedman KE, Moore GE, Morgan RT: Estrogen receptor proteins in diverse human tumors. Arch Surg. 1980;115:244-248
3. Greenway B, Iqbal MJ, Johnson PJ, Williams R: Oestrogen receptor protein in malignant and fetal pancreas. Br. Med. J. 1981;283:751-753
4. Satake K, Yoshimoto T, Mukai R, Umeyama K: Estrogenreceptors in 7,12 -dimethylbenz(a) anthracene (DMBA) induced pancreatic carcinoma in rats and in human pancreatic carcinoma. Clin. Oncol. 1982;8:49-54
5. Andren-Sandberg A, Borg S , Dawiskiba I, Ihse I, Ferno M: Estrogen- receptors and estrogen-binding protein in pancreatic cancer. Digestion 1982;25:12
6. Benz C, Wiznitzer I: Steroid binding and cytotoxicity in cultured human pancreatic carcinomas. Prog. Cancer Res. Ther. 1984;31:223-228
7. Andren-Sandberg A, Johansson J: Influence of sex hormones on pancreatic eancer. Int J. Pancreatol 1990;7:167-176
8. Japan Pancreas Society: General Rules for the Study of Pancreatic Cancer, the 4th Edition, Kanehara, Tokyo
9. Theve NO, Pousette A, Carlstrom K: Adenocarcinoma of the pancreas-a hormone sensitive tumour? A preliminary report on Norvadex treatment. Clin Oncol 1983;9:193-197
10. Tonnesen K, Kamp-Jensen M: Antiestrogen therapy in pancreatic carcinoma: a preliminary reports. Eur.J. Surg. Oncol. 1986;12:69-70
11. Crowson MC, Dorrell A, Rolfe EB, Fielding WL: A phase 11 study to evaluate tamoxifen in pancreatic adenocarcinoma. Eur.J. Surg.Oncol. 1986;12:335-336
12. Keating JJ, Johnson PJ, Gazzard BG: A prospective randomised controlled trial of lamoxifen and cyproterone acetate in pancreatic carcinoma. Br.J.Cancer 1989;60:789-792
13. Taylor OM, Benson EA, McMahon MJ and Yorkshire gastrointestinal tumour group: Clinical trial tamoxifen in patients with irresectable pancreatic adenocarcinoma. Br.J.Surg.1993;80:384-386
14. Wong A, Chan A, Arthur K: Therapy in unresectable adenocarcinoma of the pancreas. Cancer Treat. Rep 1987;71:749-750
15. Bakkevold KE, Pettersen A, Arnesjo B, Espehaug B: Tamoxifen therapy in unresectable adenocarcinoma of the pancreas and the papilla of Vater. Br.J.Surg. 1990;77:725-730
16. Horimi T, Morita S, Takeda I, Mori I, Majima K, Matsuda H, Ishikawa T: Hormone therapy of tamoxifen in resected carcinoma of the pancreas. J. Japanese Surg Soc 1993;94:730-735